固本培元方配合化疗治疗消化道恶性肿瘤的临床观察

Clinical observation on Guben Peiyuan prescription combined with chemotherapy in the treatment of digestive tract malignant tumors

目的:观察固本培元方配合化疗在消化道恶性肿瘤患者治疗中的增效减毒作用。方法:选择2021年1月―2022年6月在甘肃省武威肿瘤医院住院的消化道恶性肿瘤患者160例,按照是否愿意配合服用中药固本培元方分为联合组和化疗组各80例。化疗组患者采用常规的化疗方案进行化疗(参照《2021版中国临床肿瘤学会常见恶性肿瘤诊疗指南》);联合组患者采用与化疗组相同的化疗方案,并在化疗的同时全疗程服用固本培元方。一个治疗周期为3周,3个疗程后观察两组患者的临床疗效、卡氏评分、生活质量评分、中医证候积分、癌因性疲乏评分、消化道不良反应、骨髓抑制不良反应、肝肾功能指标等。结果:联合组和化疗组总有效率分别为90.00%(72/80)和67.50%(54/80),联合组的总有效率明显高于化疗组(P<0.05);治疗后,联合组的卡氏评分高于同组治疗前和化疗组(P均<0.05);治疗后,联合组的中医证候积分低于同组治疗前和化疗组(P均<0.05);治疗后,联合组的生活质量评分明显高于化疗组(P<0.05);治疗后,联合组的疲乏程度评分明显低于化疗组(P<0.05);治疗后,联合组的消化道不良反应、骨髓抑制不良反应、肝功能和肾功能损害比例均明显低于化疗组(P<0.05)。结论:在消化道恶性肿瘤患者治疗中,固本培元方配合化疗具有较好的临床疗效,并且能减低化疗的不良反应。

Objective:To observe the effect of increasing efficiency and reducing toxicity of Guben Peiyuan prescription(固本培元方)combined with chemotherapy on gastrointestinal malignant tumor.Methods:A total of 160 patients with gastrointestinal cancer hospitalized in Gansu Wuwei Tumour Hospital from January 2021 to June 2022 were selected and divided into the combination group and the chemotherapy group,with 80 patients in each group,according to whether they were willing to take Guben Peiyuan prescription.Patients in the chemotherapy group was treated by conventional chemotherapy regimen(reference to the 2021 edition Chinese Society of Clinical Oncology Guidelines for Diagnosis and Treatment of Common Malignant Tumors).Patients in the combination group received the same chemotherapy scheme in the chemotherapy group,and took Guben Peiyuan prescription for the whole course of treatment at the same time.One treatment cycle lasted for 3 weeks.After three courses,the clinical efficacy,Karnofsky performance status,quality of life score,TCM syndrome score,cancer-related fatigue score,gastrointestinal toxicity and side effects,bone marrow suppression toxicity and side effects,liver and kidney function indexes in the two groups were observed.Results:The total effective rate in the combination group and the chemotherapy group was 90.00%(72/80)and 67.50%(54/80)respectively,and the total effective rate in the combination group was significantly higher than that in the chemotherapy group(P<0.05).After treatment,the KPS score in the combination group was higher than that in the same group before treatment and that in the chemotherapy group(all P<0.05).After treatment,the TCM syndrome score in the combination group was lower than that in the same group before treatment and that in the chemotherapy group(all P<0.05).After treatment,the quality of life score in the combination group was significantly higher than that in the chemotherapy group(P<0.05).After treatment,the cancer-related fatigue score in the combination group was significantly lower than that in the chemotherapy group(P<0.05).After treatment,the proportion of gastrointestinal adverse reactions,myelosuppression adverse reactions,liver function and renal function damage in the combination group was significantly lower than that in the chemotherapy group(P<0.05).Conclusion:In the treatment of patients with digestive tract malignant tumors,Guben Peiyuan prescription combined with chemotherapy has good clinical efficacy,and it can reduce the adverse reactions of chemotherapy.